13 completed, 10 recruiting, 8 unknown, 5 active not recruiting. 17 Phase 2, 11 Phase 1, 4 Not applicable, 2 Phase 3, 2 Phase 4.
Follow Acute Lymphoid Leukemia: new trials by email Literature Review of Acute Lymphoid Leukemia trials Research Report on Acute Lymphoid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Arizona | 180 | 2026-10-26 | 2026-10-29 |
| Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital Acute Myeloid Leucemia, High-risk Myelodysplastic Syndrome (MDS) | Recruiting | Nantes University Hospital | 1000 | 2026-05-21 | 2026-05-29 | |
| Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL) Exercises - Leukemia, Acute Leukemia | Not applicable | Recruiting | UNC Lineberger Comprehensive Cancer Center | 40 | 2026-05-01 | 2026-08-03 |
| Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT ORCA-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Recruiting | Stanford University | 24 | 2025-12-01 | 2026-06-23 |
| Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia Inotuzumab ozogamicin - Acute Lymphoid Leukemia | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 21 | 2024-07-02 | 2024-07-30 |
| Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia Reinduction(4weeks), Cosolodation 1st(3weeks), Consolidation 2nd(3weeks) - Acute Lymphoid Leukemia | Phase 2 | Recruiting | Ho Joon Im | 90 | 2024-04-04 | 2026-07-29 |
| UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 CD19 Directed CAR T Cell - Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | University of Colorado, Denver | 29 | 2024-01-24 | 2026-03-11 |
| Study of the Medullary Microenvironment in Acute Childhood Leukemia Biological sampling in patients, Biological sampling in control patients - Acute Lymphoid Leukemia, Acute Myeloid Leukemia in Children | Not applicable | Recruiting | University Hospital, Tours | 40 | 2023-10-26 | 2025-11-24 |
| Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant No intervention - Hematologic Diseases, Chronic Myeloid Leukemia | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 144 | 2023-10-01 | 2025-12-08 | |
| Muscle Dysfunction in Patients With Haematological Diseases Hematologic Diseases, Acute Myeloid Leukemia | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 216 | 2023-10-01 | 2026-08-14 | |
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil Prednisone, Vincristin, Daunorubicin - Acute Lymphoid Leukemia, Minimal Residual Disease | Recruiting | Instituto do Cancer do Estado de São Paulo | 180 | 2023-09-05 | 2026-11-03 | |
| H19 in Acute Lymphoblastic Leukemia. Acute Lymphoid Leukemia | Unknown | Assiut University | 96 | 2023-07-01 | 2023-07-13 | |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-12-28 | 2026-10-26 |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Orca-Q - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Florida | 40 | 2022-08-16 | 2026-10-30 |
| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Orca-T, Standard-of-Care - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 3 | Active not recruiting | Orca Biosystems, Inc. | 187 | 2022-06-21 | 2026-03-04 |
| Latin American Real-world Study in Acute Leukemia Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Completed | Pfizer | 589 | 2021-12-10 | 2025-03-25 | |
| Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy ARI-0001 cells - Acute Lymphoid Leukemia | Phase 2 | Unknown | Sara V. Latorre | 50 | 2021-05-11 | 2024-06-26 |
| PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT Ruxolitinib, Tacrolimus, Mycophenolate Mofetil - Graft-versus-host-disease, Stem Cell Transplant Complications | Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 128 | 2020-11-03 | 2025-07-04 |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3 - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Withdrawn | Medigene AG | 2020-07-02 | 2021-10-08 | |
| Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Orca-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Active not recruiting | Orca Biosystems, Inc. | 155 | 2019-11-21 | 2026-08-14 |
Showing 20 of 43. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (43) · Leukemia, Myeloid, Acute (26) · Myelodysplastic Syndromes (15) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8) · Lymphoma (8) · Lymphoma, Non-Hodgkin (8) · Leukemia, Biphenotypic, Acute (6) · Multiple Myeloma (5) · Burkitt Lymphoma (4) · Hematologic Neoplasms (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Hematologic Diseases (3) · Leukemia (3) · Leukemia, B-Cell (3) · Myeloproliferative Disorders (3)
Hemic and Lymphatic Diseases (43) · Immunoproliferative Disorders (43) · Lymphatic Diseases (43) · Lymphoproliferative Disorders (43) · Neoplasms (43) · Neoplasms by Histologic Type (43) · Immune System Diseases (42) · Leukemia, Lymphoid (42) · Hematologic Diseases (40) · Leukemia (40) · Leukemia, Myeloid (26) · Bone Marrow Diseases (18) · Pathological Conditions, Signs and Symptoms (16) · Pathologic Processes (15) · Chronic Disease (11)
Cyclophosphamide (6) · Cytarabine (3) · Methotrexate (3) · asparaginase erwinia chrysanthemi recombinant (3) · Asparaginase (2) · Busulfan (2) · Doxorubicin (2) · Inotuzumab Ozogamicin (2) · Mercaptopurine (2) · Mycophenolic Acid (2) · Tacrolimus (2) · fludarabine (2) · fludarabine phosphate (2) · pegaspargase (2) · Acetaminophen (1)
Orca Biosystems, Inc. (3) · Copenhagen University Hospital, Rigshospitalet (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · National Cancer Institute (NCI) (2) · University of Florida (2) · Asan Medical Center (1) · Assiut University (1) · Chinese Academy of Medical Sciences (1) · Ho Joon Im (1) · Hospital Israelita Albert Einstein (1) · Institut Paoli-Calmettes (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Instituto do Cancer do Estado de São Paulo (1) · Isfahan University of Medical Sciences (1)
United States (17) · Brazil (3) · China (3) · France (3) · Italy (3) · Denmark (2) · Netherlands (2) · Russia (2) · South Korea (2) · Argentina (1) · Chile (1) · Colombia (1) · Germany (1) · Japan (1) · Mexico (1)
Alessandro Rambaldi (1) · Alireza Eishi, Med student (1) · Andrea Velardi, MD, PhD (1) · Boris V Afanasyev, MD, Prof. (1) · Christopher C Dvorak, M.D. (1) · Christopher R. Cogle, MD (1) · Dae-Young Kim, M.D. & PhD (1) · Eduardo M Rego, MD PhD (1) · Emmanuel Katsanis, MD (1) · Eucario Leon Rodriguez, M.D. (1) · Fabio Ciceri (1) · Fang Yongjun, Ph.D (1) · Gao Fei, Ph.D (1) · Giovanni Martinelli (1) · Ho Joon Im (1)
PMID 23624209, PMID 26994848, PMID 29222199, PMID 29360184, PMID 33646302, PMID 34398557, PMID 34687939, PMID 34889384, PMID 35605184, PMID 37486616, PMID 38319241, PMID 38376944, PMID 40009490, PMID 41385341, PMID 41651004, PMID 41671463, PMID 42066960, PMID 42248607, PMID 42806776
2018 (1), R01HL112669 (1)